search
Back to results

Improving HIV Testing, Linkage, and Retention in Care for Men Through U=U Messaging

Primary Purpose

HIV Infections, Men, Treatment Adherence

Status
Recruiting
Phase
Not Applicable
Locations
South Africa
Study Type
Interventional
Intervention
U=U testing messaging scripts
U=U adherence messaging scripts
Sponsored by
Desmond Tutu HIV Foundation
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional health services research trial for HIV Infections focused on measuring HIV, HIV testing, Men, U=U, Viral suppression, Treatment as Prevention, Viral load, ART uptake, Undetectable, Untransmittable

Eligibility Criteria

15 Years - undefined (Child, Adult, Older Adult)MaleAccepts Healthy Volunteers

Inclusion Criteria: AIM 1: male aged ≥15 years present a study issued invitation card to site receptionist ability to provide informed consent. AIM 2: cis-gender men aged ≥15 years newly initiating ART (i.e., treatment naïve) or re-initiating ART after 6 months of being lost-to-care live in Buffalo City or Cape Town Metro Health Districts provide written informed consent

Sites / Locations

  • Buffalo City MetroRecruiting
  • Cape Town MetroRecruiting

Arms of the Study

Arm 1

Arm 2

Arm 3

Arm Type

Experimental

Experimental

No Intervention

Arm Label

U=U testing messaging scripts

U=U adherence messaging scripts

Standard of Care (SoC) messaging

Arm Description

Aim 1: Human-centred designed, behavioural nudge theory informed U=U messaging intervention to improve HIV testing uptake by men

Aim 2: Human-centred designed, behavioural nudge theory informed U=U messaging intervention to improve ART adherence, HIV viral suppression and retention in care

Aim 1: SoC messaging scripts will be used to both invite men for CB-HTS and to refer those that test HIV-positive for DoH clinic-based ART initiation Aim 2: SoC messaging as part of ART initiation counselling, and as part of their HIV care and treatment program

Outcomes

Primary Outcome Measures

ART initiation among those invited to test for HIV
Proportions of ART initiation among all people invited to test in each study arm over the year of Aim 1 data collection
Proportion with viral load suppression
Proportions of people who have documented viral suppression at the 6-month visit in each study arm during Aim 2

Secondary Outcome Measures

% who agree to testing
Proportions of testing uptake among all people invited to test in each study arm over the year of Aim 1 enrolment.
Proportion retained in care
Proportions of people who have a recorded viral load at their 12-month visit in each study arm during Aim 2.

Full Information

First Posted
October 27, 2022
Last Updated
August 3, 2023
Sponsor
Desmond Tutu HIV Foundation
Collaborators
National Institute of Mental Health (NIMH), National Institutes of Health (NIH), University of Pennsylvania
search

1. Study Identification

Unique Protocol Identification Number
NCT05602376
Brief Title
Improving HIV Testing, Linkage, and Retention in Care for Men Through U=U Messaging
Official Title
Improving HIV Testing, Linkage, and Retention in Care for Men Through U=U Messaging
Study Type
Interventional

2. Study Status

Record Verification Date
August 2023
Overall Recruitment Status
Recruiting
Study Start Date
March 31, 2023 (Actual)
Primary Completion Date
December 31, 2026 (Anticipated)
Study Completion Date
May 31, 2027 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Desmond Tutu HIV Foundation
Collaborators
National Institute of Mental Health (NIMH), National Institutes of Health (NIH), University of Pennsylvania

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
Yes

5. Study Description

Brief Summary
This study will evaluate the impact of U=U messaging and counseling on gaps in the HIV care cascade for men, including testing uptake and ART initiation (Aim 1), achieving viral suppression and retention in care (Aim 2) in two provinces in South Africa. The U=U message communicates the compelling idea that PLHIV who take ART and have an undetectable viral load (<200 copies/mL) cannot sexually transmit HIV. Additionally, the investigators will conduct a multi-method evaluation to inform future implementation of U=U messaging interventions (Aim 3).
Detailed Description
Increasing the coverage of HIV testing and treatment among people living with HIV (PLHIV) is essential for ending the global AIDS epidemic. Unfortunately, compared to women, men living with HIV (MLHIV) are less likely to know their HIV status, start anti retroviral treatment, or achieve viral suppression. Given that new HIV infections among women are driven, in part, by men's testing and treatment gaps, reducing the gender gap in testing uptake, treatment initiation and achievement of viral suppression by men must be prioritized in order to accelerate the decline in HIV incidence among women, improve men's HIV-related health outcomes and achieve the UNAIDS 95-95-95 goals by 2030. In this study, the investigators evaluate the effectiveness of Undetectable Equals Untransmittable or "U=U" messaging for closing the gender gap in the HIV cascade. Particularly for men, the U=U message has the potential to accelerate progress towards the 95-95-95 targets by: 1) reducing anxiety associated with HIV testing (1st 95); 2) encouraging people who test HIV positive to initiate ART (2nd 95); and 3) reducing fear of transmitting HIV to sexual partners by promoting treatment adherence to achieve viral suppression (3rd 95). While there is a growing knowledge of Treatment as Prevention (TasP)/U=U among PLWH in Western countries, the reach and penetration of the U=U message in sub-Saharan Africa has been limited and few studies have tested the impacted of accessible U=U messages on ART uptake and adherence in sub-Saharan Africa. Building on the investigators prior work on U=U messaging informed by behavioral economics and human-centered design, they propose to conduct two hybrid type 1 effectiveness-implementation randomized controlled trials to evaluate the impact of U=U messages on men's uptake of community-based HIV testing and treatment initiation (Aim 1), and achievement of viral suppression (Aim 2). The investigators will also conduct a multi-method evaluation to inform future implementation of U=U messaging interventions. To improve the generalizability of the findings, the study will be conducted in two provinces in South Africa (Western and Eastern Cape). If effective, the intervention can shape global HIV testing and treatment counselling guidelines and practices. The expert, multi-institutional collaborations will allow for the application of previous research findings, leverage unique implementation platforms and resources, and rapidly disseminate the findings.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
HIV Infections, Men, Treatment Adherence
Keywords
HIV, HIV testing, Men, U=U, Viral suppression, Treatment as Prevention, Viral load, ART uptake, Undetectable, Untransmittable

7. Study Design

Primary Purpose
Health Services Research
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Model Description
Two hybrid type 1 effectiveness-implementation randomized controlled trials to evaluate the impact of U=U messages on men's uptake of community-based HIV testing and treatment initiation (Aim 1), and achievement of viral suppression (Aim 2)
Masking
InvestigatorOutcomes Assessor
Masking Description
Aim 1: Site-testing-days will be randomised 1:1 to implement either U=U (intervention) or SoC (Control) messaging scripts for both invitation-to-test and ART initiation. Aim 2: Randomization will be stratified by the 6 study clinics, to account for possible differences in the baseline viral loads of the catchment area populations initiating ART within each clinic with individual-level randomization will be used with random block sizes.
Allocation
Randomized
Enrollment
23188 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
U=U testing messaging scripts
Arm Type
Experimental
Arm Description
Aim 1: Human-centred designed, behavioural nudge theory informed U=U messaging intervention to improve HIV testing uptake by men
Arm Title
U=U adherence messaging scripts
Arm Type
Experimental
Arm Description
Aim 2: Human-centred designed, behavioural nudge theory informed U=U messaging intervention to improve ART adherence, HIV viral suppression and retention in care
Arm Title
Standard of Care (SoC) messaging
Arm Type
No Intervention
Arm Description
Aim 1: SoC messaging scripts will be used to both invite men for CB-HTS and to refer those that test HIV-positive for DoH clinic-based ART initiation Aim 2: SoC messaging as part of ART initiation counselling, and as part of their HIV care and treatment program
Intervention Type
Behavioral
Intervention Name(s)
U=U testing messaging scripts
Intervention Description
On site testing days randomized to the intervention, trained health promoters employed by the mobile testing venues will use U=U messaging scripts to invite men in the vicinity to seek HIV testing services on that day. On intervention days, the U=U messaging will also be used by counselors at the testing venue when referring those who test HIV positive to clinic-based ART initiation services provided by the local Department of Health
Intervention Type
Behavioral
Intervention Name(s)
U=U adherence messaging scripts
Intervention Description
After receiving standard ART initiation and adherence counselling from a DoH clinic nurse per South African National Guidelines, RCs will deliver a U=U message and hand participants a small business card with a brief U=U message on it. Participants will then receive monthly SMS booster messages (but can opt out) and monthly in-clinic booster messages during routine medical refill visits, again with a business card for messaging reinforcement.
Primary Outcome Measure Information:
Title
ART initiation among those invited to test for HIV
Description
Proportions of ART initiation among all people invited to test in each study arm over the year of Aim 1 data collection
Time Frame
30-day follow-up period
Title
Proportion with viral load suppression
Description
Proportions of people who have documented viral suppression at the 6-month visit in each study arm during Aim 2
Time Frame
6-month visit
Secondary Outcome Measure Information:
Title
% who agree to testing
Description
Proportions of testing uptake among all people invited to test in each study arm over the year of Aim 1 enrolment.
Time Frame
Baseline
Title
Proportion retained in care
Description
Proportions of people who have a recorded viral load at their 12-month visit in each study arm during Aim 2.
Time Frame
12-month visit

10. Eligibility

Sex
Male
Minimum Age & Unit of Time
15 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria: AIM 1: male aged ≥15 years present a study issued invitation card to site receptionist ability to provide informed consent. AIM 2: cis-gender men aged ≥15 years newly initiating ART (i.e., treatment naïve) or re-initiating ART after 6 months of being lost-to-care live in Buffalo City or Cape Town Metro Health Districts provide written informed consent
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Andrew Medina-Marino, PhD
Phone
+27 87 821 1109
Email
Andrew.Marino@hiv-research.org.za
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Andrew Medina-Marino, PhD
Organizational Affiliation
Desmond Tutu Health Foundation
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Alison Buttenheim, PhD, MBA
Organizational Affiliation
Penn Nursing and Perelman School of Medicine, University of Pennsylvania
Official's Role
Principal Investigator
Facility Information:
Facility Name
Buffalo City Metro
City
East London
State/Province
Eastern Cape
ZIP/Postal Code
5217
Country
South Africa
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Andrew Medina-Marino, PhD
Phone
+27 87 821 1109
Email
Andrew.Marino@hiv-research.org.za
First Name & Middle Initial & Last Name & Degree
Andrew Medina-Marino, PhD
First Name & Middle Initial & Last Name & Degree
Alison Buttenheim, PhD, MBA
Facility Name
Cape Town Metro
City
Cape Town
State/Province
Western Cape
ZIP/Postal Code
7405
Country
South Africa
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Andrew Medina-Marino, PhD
Phone
+27 87 821 1109
Email
Andrew.Marino@hiv-research.org.za
First Name & Middle Initial & Last Name & Degree
Andrew Medina-Marino, PhD
First Name & Middle Initial & Last Name & Degree
Alison Buttenheim, PhD, MBA

12. IPD Sharing Statement

Plan to Share IPD
Yes
IPD Sharing Access Criteria
Based on contractual agreement

Learn more about this trial

Improving HIV Testing, Linkage, and Retention in Care for Men Through U=U Messaging

We'll reach out to this number within 24 hrs